Icon (NASDAQ:ICLR) Stock: Insider Emer Lyons Sells 264 Shares

Icon Plc (NASDAQ:ICLR) CAO Emer Lyons sold 264 shares of Icon stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $206.66, for a total value of $54,558.24. Following the completion of the transaction, the chief accounting officer owned 1,217 shares in the company, valued at $251,505.22. This represents a 17.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emer Lyons also recently made the following trade(s):

• On Friday, October 23rd, Emer Lyons sold 272 shares of Icon stock. The stock was sold at an average price of $182.37, for a total transaction of $49,604.64.

Icon Stock Down 0.7%

Shares of Icon stock traded down $1.37 on Tuesday, reaching $203.77. The stock had a trading volume of 1,096,464 shares, compared to its average volume of 1,264,512. Icon Plc has a 1 year low of $66.57 and a 1 year high of $219.04. The company has a 50 day moving average price of $172.62 and a 200 day moving average price of $146.63. The company has a quick ratio of 0.95, a current ratio of 1.32 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $15.60 billion, a P/E ratio of 35.07, a P/E/G ratio of 13.65 and a beta of 1.24.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. Icon’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.31 EPS. As a group, equities research analysts forecast that Icon Plc will post 9.57 EPS for the current year.

Institutional Trading of Icon

A number of hedge funds and other institutional investors have recently made changes to their positions in ICLR. Polianta Ltd acquired a new position in Icon in the second quarter valued at about $1,876,000. Maple Rock Capital Partners Inc. boosted its position in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after buying an additional 864,300 shares during the period. Royal Bank of Canada grew its stake in shares of Icon by 68.0% in the first quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company’s stock valued at $17,011,000 after buying an additional 62,225 shares in the last quarter. Trinity Street Asset Management LLP raised its holdings in shares of Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock valued at $266,725,000 after buying an additional 327,314 shares during the period. Finally, VELA Investment Management LLC raised its holdings in shares of Icon by 511.4% in the 2nd quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company’s stock valued at $2,118,000 after buying an additional 10,198 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ICLR shares. TD Cowen increased their price objective on shares of Icon from $197.00 to $254.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Robert W. Baird raised their target price on Icon from $210.00 to $249.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $250.00 price target on shares of Icon in a research report on Thursday, October 29th. Mizuho set a $228.00 price objective on shares of Icon in a research note on Friday. Finally, Weiss Ratings raised shares of Icon from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Icon has an average rating of “Moderate Buy” and a consensus price target of $213.76.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.